Kintara Therapeutics, Inc is a biotechnology business based in the US. Kintara Therapeutics shares (KTRA) are listed on the NASDAQ and all prices are listed in US Dollars. Kintara Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Kintara Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – KTRA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Kintara Therapeutics stock price (NASDAQ: KTRA)Use our graph to track the performance of KTRA stocks over time.
Kintara Therapeutics shares at a glance
|Latest market close||$1.61|
|52-week range||$0.86 - $3.35|
|50-day moving average||$1.88|
|200-day moving average||$1.80|
|Wall St. target price||$5.81|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy Kintara Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Kintara Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Kintara Therapeutics price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||-16.58%|
|3 months (2021-04-30)||19.26%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
Kintara Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-92.06%|
|Return on equity TTM||-356.77%|
|Market capitalisation||$52.2 million|
TTM: trailing 12 months
Shorting Kintara Therapeutics shares
There are currently 1.6 million Kintara Therapeutics shares held short by investors – that's known as Kintara Therapeutics's "short interest". This figure is 23.2% up from 1.3 million last month.
There are a few different ways that this level of interest in shorting Kintara Therapeutics shares can be evaluated.
Kintara Therapeutics's "short interest ratio" (SIR)
Kintara Therapeutics's "short interest ratio" (SIR) is the quantity of Kintara Therapeutics shares currently shorted divided by the average quantity of Kintara Therapeutics shares traded daily (recently around 1.7 million). Kintara Therapeutics's SIR currently stands at 0.98. In other words for every 100,000 Kintara Therapeutics shares traded daily on the market, roughly 980 shares are currently held short.
However Kintara Therapeutics's short interest can also be evaluated against the total number of Kintara Therapeutics shares, or, against the total number of tradable Kintara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kintara Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Kintara Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0559% of the tradable shares (for every 100,000 tradable Kintara Therapeutics shares, roughly 56 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kintara Therapeutics.
Find out more about how you can short Kintara Therapeutics stock.
Kintara Therapeutics share dividends
We're not expecting Kintara Therapeutics to pay a dividend over the next 12 months.
Have Kintara Therapeutics's shares ever split?
Kintara Therapeutics's shares were split on a 1:10 basis on 7 May 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kintara Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Kintara Therapeutics shares which in turn could have impacted Kintara Therapeutics's share price.
Kintara Therapeutics share price volatility
Over the last 12 months, Kintara Therapeutics's shares have ranged in value from as little as $0.861 up to $3.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kintara Therapeutics's is 1.5163. This would suggest that Kintara Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Kintara Therapeutics overview
Kintara Therapeutics, Inc. , a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc.
Stocks similar to Kintara Therapeutics
Kintara Therapeutics in the news
KTRA: Phase II Topline
Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More
56 Biggest Movers From Friday
Frequently asked questionsWhat percentage of Kintara Therapeutics is owned by insiders or institutions?
Currently 1.035% of Kintara Therapeutics shares are held by insiders and 7.05% by institutions. How many people work for Kintara Therapeutics?
Latest data suggests 4 work at Kintara Therapeutics. When does the fiscal year end for Kintara Therapeutics?
Kintara Therapeutics's fiscal year ends in June. Where is Kintara Therapeutics based?
Kintara Therapeutics's address is: 12707 High Bluff Drive, San Diego, CA, United States, 92130 What is Kintara Therapeutics's ISIN number?
Kintara Therapeutics's international securities identification number is: US49720K1016
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert